SYSTEMIC RETINOIDS IN THE MANAGEMENT OF MODERATE TO-SEVERE ACNE: A CLINICAL CASE STUDY
Introduction: Acne vulgaris is a multifactorial inflammatory disorder affecting about 9% of the global population, most commonly in those aged 20–29 years. Its pathogenesis involves follicular hyperkeratinization, sebaceous hyperactivity, and immune activation, leading to inflammation and scarring, requiring targeted treatments like retinoids.
The aim of this study is to assess the clinical effectiveness of acnekutan in managing severe acne.
Materials and Methods: A retrospective case review was conducted using medical records from the dermatovenerology department of City Hospital No. 2, Abai region. The patient's condition was monitored in the CMIS from 2024 to 2025, following clinical guidelines approved by the Ministry of Health of Kazakhstan. Signed informed consent was obtained from both the clinic administration and the patient for publication.
Results: After transitioning a patient with severe acne to isotretinoin, a significant clinical improvement was observed. The treatment effectively reduced inflammatory lesions, prevented the formation of new acne elements. Clinical studies have demonstrated that acnekutan targets multiple pathogenic mechanisms of acne and enhances patients' quality of life. In our study, the patient experienced side effects such as skin dryness and a temporary increase in transaminase levels, consistent with global research findings.
Conclusion: Isotretinoin remains the preferred treatment for severe acne, ensuring high efficacy and prolonged remission. Careful monitoring and individualized dosing are essential for optimal patient management. Future research should focus on dosing optimization, combination therapies, and treatment resistance mechanisms.
Kussainova Assiya Abikhasovna - PhD, Acting Associate Professor Department of General practice with a course of evidence-based medicine, NJSC "Astana Medical University", phone: 8 707 498 73 48, e-mail: kuzilas@mail.ru, https://orcid.org/0000 0002-5738-0804, Astana, Kazakhstan;
Akhmetova Almira Kalikapasovna - Candidate of Medical Sciences, Acting Professor of the Department of Infectious Diseases, Dermatovenerology and Immunology, NJSC "Semey Medical University", phone: 8 701 388 13 37, e-mail: almirahmetova@mail.ru, https://orcid.org/0000-0002-8938-3401, Semey, Kazakhstan;
Zhunussova Dinara Kairgeldievna – Candidate of Medical Sciences, Acting Associate Professor Department of General practice with a course of evidence-based medicine, NJSC "Astana Medical University", phone: 8 701 732 42 47, e-mail: zhunussova.d@amu.kz, https://orcid.org/ 0000-0003-3851-3728, Astana, Kazakhstan;
Yurkovskaya Oxana Alexandrovna - Candidate of Medical Sciences, Acting Professor of the Department of General medical practice, NJSC "Semey Medical University", phone: 8 702 750 65 21, e-mail: Oksanayrk@mail.ru, https://orcid.org/0000-0002-6251-5574, Semey, Kazakhstan;
Dyusseneva Dinara Kenesovna - Dermatovenerologist at City Hospital № 2, phone: 8 707 695 43 74, e-mail: dermatolog19@mail.ru, Semey, Kazakhstan;
Adilgozhina Saltanat Muratbekova, - Candidate of Medical Sciences, Department of Family Medicine, NJSC Semey Medical University, phone: 8 777 851 22 18, e-mail: saltanat.adilgozhina@smu.edu.kz, https://orcid.org/0000-0002-8408-7363, Semey, Kazakhstan;
Shamshudinov Timur Maratovich – PhD, «Medical and diagnostic Center of otorhinolaryngology» PRO-LOR, phone: 8 701 204 10 70, e-mail: dr.shamshudinov@mail.ru, https://orcid.org/0000-0001-5015-871X, Almaty, Kazakhstan;
Bolekbayeva Akerke Yerbolovna - 2nd year resident, Department of Infectious Diseases, Dermatovenerology and Immunology, NJSC "Semey Medical University", phone: 8 707 697 97 95, e-mail: akerkebolekbayeva18@gmail.com, Semey, Kazakhstan;
Kassym Laura Talgatkyzy – PhD, Associate Professor Department of General practice with a course of evidence-based medicine, NJSC "Astana Medical University", phone: 8 777 735 10 62, е-mail: laura.kassym@gmail.com, https://orcid.org/0000-0003-4448-6455, Astana, Kazakhstan.
1. Altıntaş Aykan D., Ergün Y. Isotretinoin: Still the cause of anxiety for teratogenicity. Dermatol Ther. 2020. 33(1). e13192. doi: 10.1111/dth.13192. Epub 2019 Dec 27.
2. Bae I.H., Kwak J.H., Na C.H., Kim M.S., Shin B.S., Choi H. A Comprehensive Review of the Acne Grading Scale in 2023. Ann Dermatol. 36(2). 65-73. doi: 10.5021/ad.23.094.
3. Bagatin E., Costa C.S. The use of isotretinoin for acne - an update on optimal dosing, surveillance, and adverse effects. Expert Rev Clin Pharmacol. 2020. 13(8). 885-897. doi: 10.1080/17512433.2020.1796637. Epub 2020 Aug 1.
4. Clayton R.W., Langan E.A., Ansell D.M., de Vos IJHM., Göbel K., Schneider M.R., Picardo M., Lim X., van Steensel MAM., Paus R. Neuroendocrinology and neurobiology of sebaceous glands. Biol Rev Camb Philos Soc. 2020. 95(3). 592-624. doi: 10.1111/brv.12579. Epub 2020 Jan 22.
5. Collier C.N., Harper J.C., Cafardi J.A., Cantrell W.C., Wang W., Foster K.W., Elewski B.E. The prevalence of acne in adults 20 years and older. J Am Acad Dermatol. 2008. 58(1). 56-9. doi: 10.1016/j.jaad.2007.06.045. Epub 2007 Oct 22. Erratum in: J Am Acad Dermatol. 2008. 58(5). 874. Cafardi, Jennifer A [added].
6. Cong T.X., Hao D., Wen X., Li X.H., He G., Jiang X. From pathogenesis of acne vulgaris to anti-acne agents. Arch Dermatol Res. 2019. 311(5). 337-349. doi: 10.1007/s00403-019-01908-x. Epub 2019 Mar 11.
7. Del Rosso J.Q., Tanghetti E.A. The Role of Oral Isotretinoin in Acne Therapy: Why the Delay? // Journal of Clinical and Aesthetic Dermatology. 2019. 12(4). 12-16.
8. Deng Y., Wang F., He L. Skin Barrier Dysfunction in Acne Vulgaris: Pathogenesis and Therapeutic Approaches. Med Sci Monit. 2024. 30. e945336. doi: 10.12659/MSM.945336.
9. Dréno B., Bettoli V., Ochsendorf F. et al. Predictors of acne relapse following successful treatment with oral isotretinoin. Journal of the European Academy of Dermatology and Venereology. 2019. 33(1). 74-81.
10. Dreno B., Kang S., Leyden J., York J. Update: Mechanisms of Topical Retinoids in Acne. J Drugs Dermatol. 2022. 21(7). 734-740. doi: 10.36849/JDD.6890.
11. Eichenfield D.Z., Sprague J., Eichenfield L.F. Management of Acne Vulgaris: A Review. JAMA. 326(20). 2055–2067. https://doi.org/10.1001/jama.2021.17633
12. González-Mondragón E.A., Ganoza-Granados LDC., Toledo-Bahena M.E., Valencia-Herrera A.M., Duarte-Abdala M.R., Camargo-Sánchez K.A., Mena-Cedillos C.A. Acne and diet: a review of pathogenic mechanisms. Bol Med Hosp Infant Mex. 2022. 79(2). 83-90. English. doi: 10.24875/BMHIM.21000088.
13. Hauk L. Acne Vulgaris: Treatment Guidelines from the AAD. Am Fam Physician. 2017. 95(11). 740-741. PMID: 28671431.
14. Huang C., Zhuo F., Han B., Li W., Jiang B., Zhang K., Jian X., Chen Z., Li H., Huang H., Dou X., Yu B. The updates and implications of cutaneous microbiota in acne. Cell Biosci. 2023. 13(1). 113. doi: 10.1186/s13578-023-01072-w.
15. Huang Y.C., Cheng Y.C. Isotretinoin Treatment for Acne and Risk of Depression: A Systematic Review and Meta-Analysis. JAMA Dermatology. 2020. 156(8). 891-900.
16. Huang C.Y., Chang I.J., Bolick N., Hsu W.T., Su C.H., Hsieh T.S., Huang I.H., Lee C.C. Comparative Efficacy of Pharmacological Treatments for Acne Vulgaris: A Network Meta-Analysis of 221 Randomized Controlled Trials. Annals of family medicine. 2023. 21(4). 358–369. https://doi.org/10.1370/afm.2995
17. Kaur M., Singh T., Singh R. Isotretinoin in acne: Recent advances in dosing and safety. Dermatologic Therapy. 2019. 32(3). e12892.
18. Kolli S.S., Pecone D., Pona A., Cline A., & Feldman S.R. Topical Retinoids in Acne Vulgaris: A Systematic Review. American journal of clinical dermatology. 2019. 20(3). 345–365. https://doi.org/10.1007/s40257-019-00423-z
19. Latter G., Grice J.E., Mohammed Y., Roberts M.S., Benson H.A.E. Targeted Topical Delivery of Retinoids in the Management of Acne Vulgaris: Current Formulations and Novel Delivery Systems. Pharmaceutics. 2019. 11(10). 490. https://doi.org/10.3390/pharmaceutics11100490
20. Layton A.M., Eady E.A., Whitehouse H. Oral isotretinoin: A reappraisal of risks and benefits // British Journal of Dermatology. 2021. 185(5). 935-942.
21. Leung A.K., Barankin B., Lam J.M., Leong K.F., & Hon K.L. Dermatology: how to manage acne vulgaris. Drugs in context. 2021. 10. 8-6. https://doi.org/10.7573/dic.2021-8-6
22. Leyden J., Stein-Gold, L. & Weiss J. Why Topical Retinoids Are Mainstay of Therapy for Acne. Dermatology and therapy. 2017. 7(3). 293–304. https://doi.org/10.1007/s13555-017-0185-2
23. Mavranezouli I., Daly C.H., Welton N.J., Deshpande S., Berg L., Bromham N., Arnold S., Phillippo D.M., Wilcock J., Xu J., Ravenscroft J.C., Wood D., Rafiq M., Fou L., Dworzynski K., & Healy E. A systematic review and network meta-analysis of topical pharmacological, oral pharmacological, physical and combined treatments for acne vulgaris. The British journal of dermatology. 2022. 187(5). 639–649. https://doi.org/10.1111/bjd.21739
24. Melnik B.C. Acne Transcriptomics: Fundamentals of Acne Pathogenesis and Isotretinoin Treatment. Cells. 2023. 12(22). 2600. doi: 10.3390/cells12222600.
25. Mohsin N., Hernandez L.E., Martin M.R., Does A.V., Nouri K. Acne treatment review and future perspectives. Dermatol Ther. 2022. 35(9). e15719. doi: 10.1111/dth.15719. Epub 2022 Jul 26.
26. Pile H.D., Sadiq N.M. Isotretinoin. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30247824.
27. Rademaker M., Wishart J.M. Adverse effects of isotretinoin: A retrospective review. Australasian Journal of Dermatology. 2019. 60(1). 49-53.
28. Tan J.K.L., Stein Gold L.F, Alexis A.F., Harper J.C. Current Concepts in Acne Pathogenesis: Pathways to Inflammation. Semin Cutan Med Surg. 2018. 37(3S). S60-S62. doi: 10.12788/j.sder.2018.024.
29. Tan J., Knezevic S., Boyal S., Waterman B., & Janik T. Evaluation of Evidence for Acne Remission With Oral Isotretinoin Cumulative Dosing of 120-150 mg/kg. Journal of cutaneous medicine and surgery. 20(1). 13–20. https://doi.org/10.1177/1203475415595776
30. Thiboutot D.M., Dréno B., Abanmi A., Alexis A. F., Araviiskaia E., Barona Cabal M.I., Bettoli V., Casintahan F., Chow S., et al. Practical management of acne for clinicians: An international consensus from the Global Alliance to Improve Outcomes in Acne. Journal of the American Academy of Dermatology. 2018. 78(2 Suppl 1). S1–S23.e1. https://doi.org/10.1016/j.jaad.2017.09.078
31. Zaenglein A.L., Pathy A.L., Schlosser B.J. et al. Guidelines of care for the management of acne vulgaris. Journal of the American Academy of Dermatology. 2018;74(5):945-973.
32. Zouboulis C.C., Coenye T., He L., Kabashima K., Kobayashi T., Niemann C., Nomura T., Oláh A., Picardo M., Quist S.R., Sasano H., Schneider M.R., Törőcsik D., Wong S.Y. Sebaceous immunobiology - skin homeostasis, pathophysiology, coordination of innate immunity and inflammatory response and disease associations. Front Immunol. 2022. 13. 1029818. doi: 10.3389/fimmu.2022.1029818.
Количество просмотров: 618
Категория статей:
Клинический случай
Библиографическая ссылка
Kussainova A.A., Akhmetova A.K., Zhunussova D.K., Yurkovskaya O.A., Dyusseneva D.K., Adilgozhina S.M., Shamshudinov T.M., Bolekbayeva A.Y., Kassym L.T. Systemic retinoids in the management of moderate-to-severe acne: a clinical case study // Nauka i Zdravookhranenie [Science & Healthcare]. 2025. Vol.27 (1), pp. 274-280. doi 10.34689/SH.2025.27.1.030Похожие публикации:
SYSTEMIC RETINOIDS IN THE MANAGEMENT OF MODERATE TO-SEVERE ACNE: A CLINICAL CASE STUDY
COMMUNITY-ACQUIRED PNEUMONIA IN PREGNANT. CLINICAL CASE.
A CASE OF AUTOIMMUNE COMPLICATIONS FOLLOWING COVID-19 VACCINATION WITH SINOVAC-CORONAVAC (CHINA)
ЭОЗИНОФИЛЬНОЕ ПОРАЖЕНИЕ ЖЕЛУДОЧНО-КИШЕЧНОГО ТРАКТА У ДЕТЕЙ. КЛИНИЧЕСКИЙ СЛУЧАЙ.
USE OF A NEW DEVICE FOR DRAINAGE OF THE PLEURAL CAVITY IN CHILDREN